Skip to main content
Clinical Trials/NCT00938418
NCT00938418
Unknown
Phase 2

Phase II Study on Dose Escalated, Accelerated Hypofractionated Intensity Modulated Radiotherapy for Stage III Non-Small Cell Lung Cancer With Concurrent Chemotherapy

National University Hospital, Singapore2 sites in 1 country43 target enrollmentJuly 2009

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Stage III Non-Small Cell Lung Cancer
Sponsor
National University Hospital, Singapore
Enrollment
43
Locations
2
Primary Endpoint
Overall survival
Last Updated
16 years ago

Overview

Brief Summary

Locally advanced non-small cell lung cancer can be treated successfully with chemotherapy and radiation. However, the cure rate is low.

This study is carried out to find out whether giving radiotherapy at a higher dose over fewer treatment sessions with intensity modulated radiotherapy (IMRT) can improve the treatment outcome.

This study aims to recruit 43 patients from National University Hospital and Tan Tock Seng Hospital over a period of about 2 years.

Registry
clinicaltrials.gov
Start Date
July 2009
End Date
July 2011
Last Updated
16 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Pathologically proven (either histologic or cytologic) diagnosis of Stage IIIA or IIIB non-small cell lung cancer; excluding patients with N3 disease based on supraclavicular or contralateral hilar adenopathy, or significant pleural / pericardial effusion.

Exclusion Criteria

  • Patients for whom treatment is planned with a maximum dose of ≥ 66 Gy to the ipsilateral brachial plexus
  • Greater than minimal, exudative, or cytologically positive pleural effusions
  • ≥ 10% weight loss within the past month
  • Prior invasive malignancy (with exceptions)
  • Prior radiotherapy to the region of the study cancer
  • Significant co-morbidities
  • Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
  • Known allergic reactions to components of planned chemotherapy regimen

Outcomes

Primary Outcomes

Overall survival

Time Frame: 2 years

Secondary Outcomes

  • Response rate, locoregional control, disease free survival, toxicity(2 years)

Study Sites (2)

Loading locations...

Similar Trials